Skip to main content
HCPCS Q5169 · Level II · Part B drug

Q5169: pegfilgrastim-unne (Armlupeg), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q5169

Billing unit
0.5 MG
Inj, armlupeg, 0.5 mg
ASP payment limit
$519.481
October 2026
Practitioner MUE
none published
CMS publishes no MUE for this code
OPPS status
SI K
APC 0976
NCCI exposure
no PTP pairs
Coverage articles
1
4 states

TL;DR

HCPCS Q5169 is the Level II code for Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg, billed per 0.5 MG. The Medicare Part B ASP payment limit for October 2026 is $519.481 per billing unit. Under OPPS it carries status indicator K in APC 0976. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. Other HCPCS codes whose descriptor names pegfilgrastim: Q5130 (biosimilar pegfilgrastim-pbbk (Fylnetra) from Amneal Pharmaceuticals, LLC); Q5127 (biosimilar pegfilgrastim-fpgk (Stimufend)); Q5122 (biosimilar pegfilgrastim-apgf (Nyvepria) from Pfizer Inc); Q5120 (biosimilar pegfilgrastim-bmez (Ziextenzo) from Sandoz Inc); Q5111 (biosimilar pegfilgrastim-cbqv (Udenyca)); Q5108 (biosimilar pegfilgrastim-jmdb (Fulphila)). The ASP crosswalk maps 1 NDC to it, sold as Armlupeg by Lupin Pharmaceuticals, Inc. 1 Medicare coverage article lists the code across 4 states, including A56748.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q5169 at $519.481 per 0.5 MG for October 2026, derived from manufacturer average sales price plus 6%. Beneficiary coinsurance is 20%.

ASP payment limits for Q5169
QuarterPayment limitPerCoinsurance
October 2026$519.4810.5 MG20%
July 2026n/a0.5 MG—
CMS note: Added October 2026

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to Q5169. Report the NDC in the claim's drug segment and bill the number of Q5169 units that equals the quantity administered divided by 0.5 MG; the last column gives units per full package.

NDCs that crosswalk to Q5169
NDCDrug nameLabelerPackage sizeBilling units / package
70748-0273-01ArmlupegLupin Pharmaceuticals, Inc.0.6 × 112

Medically Unlikely Edits (MUE)

CMS does not publish an MUE for Q5169 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.

MUE for Q5169 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q5169 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q5169 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q5169 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists Q5169 in their HCPCS tables, covering 4 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing Q5169
ArticleTitleContractor(s)StatesRelated LCD
A56748Billing and Coding: White Cell Colony Stimulating FactorsPalmetto GBANC SC VA WVL37176

Diagnoses Medicare contractors cover for Q5169

One billing and coding article attaches a covered diagnosis list to Q5169: 1,265 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for Q5169
ICD-10-CMDescription (FY2027)Articles covering
C00.0Malignant neoplasm of external upper lip1 of 1
C00.1Malignant neoplasm of external lower lip1 of 1
C00.2Malignant neoplasm of external lip, unspecified1 of 1
C00.3Malignant neoplasm of upper lip, inner aspect1 of 1
C00.4Malignant neoplasm of lower lip, inner aspect1 of 1
C00.5Malignant neoplasm of lip, unspecified, inner aspect1 of 1
C00.6Malignant neoplasm of commissure of lip, unspecified1 of 1
C00.8Malignant neoplasm of overlapping sites of lip1 of 1
C00.9Malignant neoplasm of lip, unspecified1 of 1
C01Malignant neoplasm of base of tongue1 of 1
C02.0Malignant neoplasm of dorsal surface of tongue1 of 1
C02.1Malignant neoplasm of border of tongue1 of 1
C02.2Malignant neoplasm of ventral surface of tongue1 of 1
C02.3Malignant neoplasm of anterior two-thirds of tongue, part unspecified1 of 1
C02.4Malignant neoplasm of lingual tonsil1 of 1
1,250 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to Q5169 are counted here: a group whose instructions name Q5169, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to Q5169, by article
ArticleContractorGroups that applyCovered codes for Q5169Full list
A56748Palmetto GBA11 groups apply to Q51691,265On LCD L37176

Local coverage policies that list Q5169

1 active Local Coverage Determination lists Q5169 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q5169 carries status indicator K and is assigned to APC 0976, with a published national unadjusted payment of $519.48. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q5169 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $519.48 per 0.5 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q5169 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q5169

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q5169

What does HCPCS code Q5169 describe?

Q5169 is defined by CMS as "Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg". Each billing unit represents 0.5 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q5169 a CPT code?

No. Q5169 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as pegfilgrastim-unne (Armlupeg); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q5169 reports the drug itself in 0.5 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q5169 in October 2026?

The ASP-based payment limit is $519.481 per 0.5 MG, with 20% beneficiary coinsurance. Commercial payers use their own fee schedules.

Which NDCs map to Q5169?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Armlupeg (Lupin Pharmaceuticals, Inc.). For example NDC 70748-0273-01 (package size 0.6) equals 12 billing units of Q5169.

Does Q5169 have NCCI bundling edits?

No active practitioner PTP pairs list Q5169 as a column-1 or column-2 code in the v323r0 release.

Q5169 vs Q5130: what is the difference?

Both are HCPCS Level II codes whose descriptor names pegfilgrastim. What sets Q5130 apart: biosimilar pegfilgrastim-pbbk (Fylnetra) from Amneal Pharmaceuticals, LLC. Q5169 is billed per 0.5 mg, limit $519.481; Q5130 is billed per 0.5 mg, limit $94.292, MUE 12. Report the code whose descriptor matches the product and setting in the record.

Q5169 vs Q5127: what is the difference?

Both are HCPCS Level II codes whose descriptor names pegfilgrastim. What sets Q5127 apart: biosimilar pegfilgrastim-fpgk (Stimufend). Q5169 is billed per 0.5 mg, limit $519.481; Q5127 is billed per 0.5 mg, limit $163.948, MUE 12. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention Q5169?

1 current Billing and Coding Article in the Medicare Coverage Database lists Q5169, covering 4 states: A56748 (Billing and Coding: White Cell Colony Stimulating Factors).

What diagnosis codes support Q5169?

One Medicare billing and coding article lists 1,265 covered ICD-10-CM codes for Q5169, for example C00.0 (Malignant neoplasm of external upper lip); C00.1 (Malignant neoplasm of external lower lip); C00.2 (Malignant neoplasm of external lip, unspecified); C00.3 (Malignant neoplasm of upper lip, inner aspect); C00.4 (Malignant neoplasm of lower lip, inner aspect). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.